🇺🇸 FDA
Pipeline program

Vortioxetine 10 mg/day

12709A

Phase 3 small_molecule completed

Quick answer

Vortioxetine 10 mg/day for Depressive Disorder, Major is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Depressive Disorder, Major
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials